Lineage Cell Therapeutics, Inc.
Profit Margins
| Fiscal Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| FY2016 | 94.0% | -995.6% | 566.8% |
| FY2017 | 95.1% | -1,125.0% | -577.7% |
| FY2018 | 93.9% | -837.9% | -922.0% |
| FY2019 | 88.3% | -1,106.0% | -333.1% |
| FY2020 | 78.9% | -1,448.4% | -1,130.8% |
| FY2021 | 67.2% | -1,133.6% | -991.0% |
| FY2022 | 95.0% | -153.2% | -178.7% |
| FY2023 | 92.5% | -276.5% | -240.2% |
| FY2024 | 96.5% | -226.1% | -195.9% |
| FY2025 | — | -251.6% | -436.5% |